Post-Hoc: AI bio needs to heed the overhyped history of CRISPR
Recent commentary highlights the need for the AI bio sector to learn from the overhyped history of CRISPR, which saw significant early excitement but also unfulfilled expectations.
A biotechnology company focused on reproductive health recently secured $65 million in funding, underscoring ongoing investment in advanced biotech despite the cautionary note about hype.
The article suggests that while AI and biotech convergence is powerful, overpromising can lead to disillusionment similar to what was seen with CRISPR, and advocates for a measured outlook.